Another unreasonable suppression! The U.S. House of Representatives has passed the Biosecurity Act, and wuxi apptec and wuxi bio have quickly responded.
①The U.S. House of Representatives passed the draft of the Biosecurity Act (H.R.8333) with 306 votes in favor and 81 votes against. ②Wuxi Apptec, Wuxi Bio, and other companies strongly opposed it. ③This bill still needs to be voted on by the Senate and the versions passed by both houses need to be reconciled before it can be submitted to the U.S. President for signing into law.
A subsidiary has been "blacklisted" by Shenzhen for one year. Jointown Pharmaceutical Group claims to be "in the process of defending". The industry believes that the intensity of procurement supervision is continuously increasing.
Recently, Jointown Pharmaceutical Group's subsidiary, Jointown Medical Device, was fined and banned from participating in Shenzhen procurement for one year due to providing false information in a tender at a hospital in Shenzhen. Jointown Pharmaceutical Group responded to a reporter from Caijing.com.cn, stating that this incident is a pending matter, and they have organized appeal materials and are currently undergoing administrative reconsideration. This year, several listed companies have been fined for violations in the bidding and procurement process, leading industry insiders to suggest that companies should pay more attention to compliance with details during the bidding process.
Is the GLP-1 pipeline progressing slowly? Gan & Lee Pharmaceuticals: GZR18 has the potential for superior weight reduction efficacy compared to multi-target drugs | Live coverage of the earnings conference.
At the earnings conference, the management of Gan & Lee Pharmaceuticals emphasized that the price regression of the company's insulin products in the follow-up volume procurement has driven the performance. In the face of doubts about the progress of GLP-1 pipeline research and competitiveness, Dou Kai, the General Manager of Gan & Lee Pharmaceuticals, stated that GZR18 injection has a weight loss effect that exceeds exenatide and dulaglutide, and has the potential to be superior to multi-target GLP-1RA drugs in weight loss efficacy.
Zhejiang Hisun Pharmaceutical: Give up the pharmaceutical distribution raw material business, leading to a decline in H1 revenue. Sales of Olsalazine increased significantly compared to the same period last year.
①At the earnings conference, the CFO of Zhejiang Hisun Pharmaceutical explained that the decline in H1 revenue was due to the company's abandonment of low-margin pharmaceutical distribution raw material business and other factors. ②President Xiao Weihong addressed questions about the growth in endocrine drug revenue and the future business model of the animal health sector.
chongqing zhifei biological products' 23-valent pneumonia vaccine joins the "price reduction group" just one year after its launch.
① Chongqing Zhifei Biological Products 23-valent pneumococcal polysaccharide vaccine has lowered its online price by nearly 30% in provinces such as Jiangsu and Jilin; ② Currently, China's pneumococcal vaccine market is showing a competitive situation of "wrestling" between overseas MNCs and domestic companies, and more and more companies are expanding their presence in this field; ③ Industry experts believe that in order to occupy the market, companies can only choose to actively reduce prices.
The batch issuance of the quadrivalent HPV vaccine has dramatically decreased, and chongqing zhifei biological products' revenue and net profit have both declined. Interpretation of the financial report.
Due to the decrease in sales volume of H1's main products, Chongqing Zhifei Biological Products reported a decrease in revenue and net income in its semi-annual report. The volume of Merck's quadrivalent HPV vaccine, which the company represents, decreased by more than 90% compared to the previous year. With the accelerated development of domestically-produced nine-valent HPV vaccines, the company's pressure will further increase.